Radici E, Persiani P, Stroppa S, Lombardi P L, Torre G C
Divisione di Ostetricia e Ginecologia I, Ospedali Riuniti, Bergamo.
Minerva Ginecol. 1996 Jan-Feb;48(1-2):5-9.
To evaluate the use of UGP (urinary gonadotropin protein) as a tumor marker in gynaecologic and obstetric malignant diseases.
The study was carried out in the division of Gynaecology and Obstetrics of the Ospedali Riuniti in Bergamo. 63 patients, with obstetric or gynaecologic benign or malignant diseases, entered the study. 66 healthy volunteers were examined as a group-control. In both the groups UGP levels were determined in morning urine, using an immunoenzymatic commercial kit.
Results, expressed in fmol UGP/ml of urin, show that UGP is produced by several neoplasms, but the false-positive percentage is still high; a higher precision can be obtained with an accurate choice of the cut-off value and with a standardization of the analytical technics. Besides, the contemporary determination of UGP and CA 125 levels reduces the possibility of false-positive and false-negative results.
More studies must be carried out to confirm the value of UGP as a tumor marker in obstetrics and gynaecology. Anyway, this recently purified protein can already be useful, in combination with the usual tumor markers, in the prompt diagnosis and management of primary neoplasms or recurrences, with a higher sensibility in comparison with traditional clinical and radiological examinations.
评估尿促性腺激素蛋白（UGP）作为妇产科恶性疾病肿瘤标志物的应用价值。
本研究在贝加莫综合医院妇产科进行。63例患有妇产科良性或恶性疾病的患者纳入研究。66名健康志愿者作为对照组接受检查。两组均使用免疫酶法商用试剂盒测定晨尿中的UGP水平。
以每毫升尿中fmol UGP表示的结果表明，多种肿瘤均可产生UGP，但假阳性率仍然较高；通过准确选择临界值和分析技术标准化可获得更高的精度。此外，同时测定UGP和CA 125水平可降低假阳性和假阴性结果的可能性。
必须开展更多研究以证实UGP作为妇产科肿瘤标志物的价值。无论如何，这种最近纯化的蛋白质与常用肿瘤标志物联合使用，在原发性肿瘤或复发肿瘤的快速诊断和管理中已具有实用价值，与传统临床和放射学检查相比具有更高的敏感性。
